Discovering MicroRNAs from deep sequencing data using MiRDeep

Max Delbrück Centrum für Molekulare Medizin, Robert-Rössle-Strasse 10, D-13125 Berlin-Buch, Germany.
Nature Biotechnology (Impact Factor: 41.51). 05/2008; 26(4):407-15. DOI: 10.1038/nbt1394
Source: PubMed


The capacity of highly parallel sequencing technologies to detect small RNAs at unprecedented depth suggests their value in systematically identifying microRNAs (miRNAs). However, the identification of miRNAs from the large pool of sequenced transcripts from a single deep sequencing run remains a major challenge. Here, we present an algorithm, miRDeep, which uses a probabilistic model of miRNA biogenesis to score compatibility of the position and frequency of sequenced RNA with the secondary structure of the miRNA precursor. We demonstrate its accuracy and robustness using published Caenorhabditis elegans data and data we generated by deep sequencing human and dog RNAs. miRDeep reports altogether approximately 230 previously unannotated miRNAs, of which four novel C. elegans miRNAs are validated by northern blot analysis.

Download full-text


Available from: Catherine Adamidi,
133 Reads
  • Source
    • "The remaining unique small RNA sequences were mapped to miRBase, and matched sequences were counted as known miRNAs. Mirdeep was used to identify novel miRNAs from unannotated sequences [20] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Immune thrombocytopenia (ITP), also known as idiopathic thrombocytopenic purpura, is an autoimmune disease characterized by low platelet count and increased bleeding tendency. Currently, glucocorticoid and splenectomy are the main therapies for ITP but with obvious side effects including tendency of relapse and risk of internal bleeding. In this study, we report the Mongolian medicine Qishunbaolier (QSBLE) can significantly and efficiently increase platelet count with a low recurrent rate and unnoticeable side effect. We profiled the microRNA (miRNA) expression in the blood sample of ITP patients and identified 44 miRNAs that are differentially expressed in ITP patients before and after QSBLE treatment. Out of these 44 miRNAs, 25 are expressed in control subjects and are downregulated in ITP patients, whereas the treatment with QSBLE restores their expressions to the level of control subjects. This result suggests that abnormal expression of these 25 miRNAs might be connected to the pathogenesis of ITP. Interestingly, 14 of those 44 miNRAs are predicted to target at least once on 31 known IPT associated genes, indicating the possible mechanism of QSBLE on ITP therapy.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 08/2015; 75. DOI:10.1016/j.biopha.2015.07.022 · 2.02 Impact Factor
  • Source
    • "Primary data analysis was done using the Illumina CASAVA Pipeline software v.1.8.2, and the sequence reads were further processed by trimming for adapters and filtering for low quality using Trimmomatic (Lohse et al., 2012). Identification of conserved and novel candidate microRNA genes in the bowhead genome was accomplished by applying the miRDeep2 algorithm (Friedlä nder et al., 2008, 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Graphical Abstract Highlights d Genome and two transcriptomes of the bowhead whale, the longest-lived mammal d Bowhead-specific mutations in genes associated with cancer and aging (e.g., ERCC1) d Duplications in genes associated with DNA repair, cell cycle, and aging (e.g., PCNA) d Changes in genes related to thermoregulation (UCP1) and other bowhead traits Correspondence In Brief The bowhead whale is the longest-lived mammal, possibly living over 200 years. Keane et al. sequence the bowhead genome and transcriptome and perform a comparative analysis with other cetaceans and mammals. Changes in bowhead genes related to cell cycle, DNA repair, cancer, and aging suggest alterations that may be biologically relevant.
    Cell Reports 01/2015; 10(1):112-122. DOI:10.1016/j.celrep.2014.12.008 · 8.36 Impact Factor
  • Source
    • "and miRNA counts generated for each sample [1]. Both miRDeep [5] and miRExpress 2.0 [6] were used to generate counts, and each provided comparable results, with over 50% of the reads mapping to miRNAs in either the human or EBV genomes (Table 3). Identification of known miRNAs was based on miRBase Release 19 [7], with an alignment identity of 1%, a tolerance range of 4, and a similarity threshold of 0.8 [1]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nasopharyngeal carcinoma (NPC) is a non-lymphomatous, squamous-cell carcinoma that occurs in the epithelial lining of the nasopharynx. Nasopharyngeal carcinoma has a geographically well-defined distribution worldwide, with the highest prevalence in China, Southeast Asia, and Northern Africa. Symptoms of nascent NPC may be un-apparent or trivial, with diagnosis based on the histopathology of biopsied tissue following endoscopy of the na-sopharynx. The tumor node metastasis (TNM) staging system is the benchmark for the prognosis of NPC and guides treatment strategy. However, there is a consensus that the TNM system is not sufficiently specific for the prognosis of NPC, as it does not reflect the biological heterogeneity of this tumor, making another biomarker for the detection of NPC a priority. We have previously reported on different approaches for microRNA (miRNA) biomarker discovery for Formalin Fixed Paraffin Embedded (FFPE) NPC tissue samples by both a targeted (micro-array) and an untargeted (small RNA-Seq) discovery platform. Both miRNA discovery platforms produced similar results, narrowing the miRNA signature to 1–5% of the known mature human miRNAs, with untargeted (small RNA-Seq approach) having the advantage of indicating "unknown" miRNAs associated with NPC. Both miRNA profiles strongly associated with NPC, providing two potential discovery platforms for biomarker signatures for NPC. Herein, we provide a detailed description of the methods that we used to interrogate FFPE samples to discover biomarkers for NPC.
    Genomics Data 12/2014; 2:285-289. DOI:10.1016/j.gdata.2014.08.005
Show more